Where are we going? Where have we been? What is the future? Last month, Tempus purchased Paige AI for $81M, largely in the form of Tempus stock to, as reports mention, for PaigeAI's datasets from 7 million slides, perhaps most of...

Lumea, a leader in digital pathology solutions, has chosen Tempus, a leader in artificial intelligence and precision medicine, to create AI-enabled solutions LEHI, UTAH, UNITED STATES, August 4, 2022 /EINPresswire.com/ -- Lumea Inc, a leader...

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable...